ACAD - ACADIA Pharmaceuticals Inc. Latest News | Finranks

ACAD - ACADIA Pharmaceuticals Inc. Latest News | Finranks

Why Is Acadia (ACAD) Down 12.9% Since Last Earnings Report?

Why Is Acadia (ACAD) Down 12.9% Since Last Earnings Report?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback

Bank of America upgraded Acadia Pharmaceuticals (NASDAQ:ACAD) to 'Buy' from 'Neutral', arguing that a recent pullback in the stock has created a more attractive risk-reward profile for investors. The analysts maintained a $29 price objective on the shares, which traded up 6% at $22 on Wednesday afternoon, and wrote that the roughly 25% decline in the stock is “not related to fundamentals and more related to YTD macro factors.

Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:00 a.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia.

JAZZ or ACAD: Which Is the Better Value Stock Right Now?

JAZZ or ACAD: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Jazz Pharmaceuticals (JAZZ) or Acadia Pharmaceuticals (ACAD). But which of these two stocks offers value investors a better bang for their buck right now?

ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised)

ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised)

Acadia plans re-examination after CHMP rejects Rett syndrome drug trofinetide in the EU, delays potential approval despite positive LAVENDER study results.

ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU

ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU

Acadia plans re-examination after CHMP rejects Rett syndrome drug trofinetide in the EU, delays potential approval despite positive LAVENDER study results.

Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company's Audit Committee and brings deep biopharmaceutical finance leadership experience in supporting global growth and innovation across multiple therapeutic areas and modalities. “Jonathan brings extensive biotechnology corporate leadership experience and a proven track record of supporting.

Videos

No Data

There is no data to display